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So far, two genes associated with familial melanoma have been iden-
tified, accounting for a minority of genetic risk in families.
Mutations in CDKN2A account for approximately 40% of familial
cases1, and predisposingmutations in CDK4 have been reported in a
very small number of melanoma kindreds2. Here we report the
whole-genome sequencing of probands from several melanoma
families, which we performed in order to identify other genes asso-
ciatedwith familialmelanoma.We identify one individual carrying a
novel germline variant (coding DNA sequence c.G1075A; protein
sequence p.E318K; rs149617956) in the melanoma-lineage-specific
oncogene microphthalmia-associated transcription factor (MITF).
Although the variant co-segregated with melanoma in some but
not all cases in the family, linkage analysisof31 families subsequently
identified to carry the variant generated a log of odds (lod) score
of 2.7 under a dominant model, indicating E318K as a possible
intermediate risk variant. Consistent with this, the E318K variant
was significantly associated with melanoma in a large Australian
case–control sample. Likewise, it was similarly associated in an
independent case–control sample from the United Kingdom. In
the Australian sample, the variant allele was significantly over-
represented in cases with a family history of melanoma, multiple
primary melanomas, or both. The variant allele was also associated
with increased naevus count and non-blue eye colour. Functional
analysis of E318K showed that MITF encoded by the variant
allele had impaired sumoylation and differentially regulated several
MITF targets. These data indicate that MITF is a melanoma-
predisposition gene and highlight the utility of whole-genome
sequencing to identify novel rare variants associated with disease
susceptibility.
Cutaneous malignant melanoma is predominantly a disease of fair-
skinned individuals. Aetiology is complex, with environmental
(mainly ultraviolet radiation exposure) and genetic factors affecting
disease risk. Phenotypic risk factors, which are largely heritable,
include pigmentation (fair skin, blue or green eyes, blonde or red hair),
sun sensitivity, an inability to tan3–6, high number of melanocytic
naevi7,8, or the presence of clinically atypical naevi7. Candidate-gene
studies and genome-wide association studies (GWAS) for melanoma
and these melanoma-associated phenotypes have identified several
variants associated with melanoma risk in the general population9–13.
Family studies, on the other hand, have identified only two high-
penetrance melanoma genes, CDKN2A (ref. 1) and CDK4 (ref. 2),
accounting for a minority of genetic risk in melanoma families.
As part of a larger sequencing effort to identify novelmelanoma risk
genes, we sequenced the genome of an affected individual from an
eight-case melanoma family negative for alterations in CDKN2A or
CDK4 (Fig. 1, FAM1) using a nanoarray-based short-read sequencing-
by-ligation strategy14. From among the 410 novel variants predicted to
affect protein structure, we prioritized for follow-up a single nucleotide
polymorphism (SNP) resulting in a glutamic acid to lysine substitution
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Figure 1 | Co-segregation analysis of the MITF E318K variant in the family
in which it was identified. The pedigree shows individuals that have had
melanoma (shaded circles or boxes), with the age of first melanoma diagnosis
indicated in brackets and the number of melanomas that have occurred in the
individual so far (for example, 3 2 indicates two primary melanomas). If the
number of melanomas is not stated, the individual has had a single melanoma.
A diagonal line through the symbol indicates that the person is deceased. The
genotype for theMITF E318K variant for individuals with an available DNA
sample for testing is annotated ‘E318K’ if a carrier or wild type ‘WT’. Other
cancer types are also indicated with the age of first diagnosis indicated in
brackets if known. Br, breast; Mes, mesothelioma; MM, melanoma; Oes,
oesophagus. The individual circled in Family 1 (FAM1) is themelanoma case in
which theMITF E318K variant was discovered through whole-genome
sequencing. See Supplementary Fig. 3 for pedigrees of all other families
identified as carrying E318K.
1 D E C E M B E R 2 0 1 1 | V O L 4 8 0 | N A T U R E | 9 9
Macmillan Publishers Limited. All rights reserved©2011
in MITF (E318K, codon numbering based on the melanocyte-specific
MITF-M isoform; c.G1075A, NCBI accession NM_000248.3;
p.E318K, NCBI accession NP_000239.1; rs149617956). Although
linkage15 andGWAS studies9,10 have not provided evidence implicating
MITF in either predisposition to melanoma or the melanoma-
associated phenotypes of pigmentation and naevogenesis11,12,16–19,
MITF is known to regulate a broad repertoire of genes whose functions
in melanocytes range from development, differentiation, survival,
cell-cycle regulation and pigment production. MITF is somatically
amplified20,21 ormutated22 in a subset ofmelanomas, and strongly over-
expressed in others20, making it an attractive candidate despite the lack
of prior evidence for involvement in germline risk.
We evaluatedwhetherMITFE318K is a high-penetrancemelanoma
susceptibility variant in Family 1 by genotyping the remaining affected
individuals available for study. The MITF variant allele was found in
3/7 melanoma cases assessed in this family (Fig. 1), consistent with it
being a medium-penetrance melanoma risk variant. To assess further
this possibility, we genotyped two large Australian melanoma case–
control samples forMITF E318K. The variant was found in 14/1,953
controls (carrier frequency5 0.0072) and thus represents a rare popu-
lation variant (Table 1). We observed a significantly higher frequency
(34/2,059) in cases (carrier frequency5 0.0165) than controls (Fisher
exact P5 0.008, odds ratio (OR) 2.33, 95% confidence interval (CI)
1.21–4.70), indicating that the variant correlates with increased
melanoma risk in the general population. The effect size for E318K
is larger than those reported for variants from melanoma GWAS9,10
and similar to that observed for red-hair-colour-associated variants of
the melanocortin 1 receptor (MC1R) gene (OR for most populations
,2.4)23. Among cases, theMITF E318K variant was enriched in those
with multiple primary melanomas (OR 4.22, 95% CI 1.52–10.91), a
family history of melanoma (OR 2.95, 95%CI 1.23–6.92), or both (OR
8.37, 95% CI 2.58–23.80), but not in cases with earlier age of onset
(comparing diagnosis before age 40 versus after 40 years) (Table 2).
We replicated these findings in two independent population-based
case–control samples from the United Kingdom. In the combined UK
sample, the variant allele frequency was also significantly higher in
cases (carrier frequency5 0.0176) than controls (carrier frequency5
0.0085, P5 0.012, OR 2.09, 95% CI 1.14–3.94, Table 1). The asso-
ciation with melanoma in the pooled UK and Australian data was
highly significant (combined P5 0.0003, OR 2.19, 95% CI 1.41–
3.45). In the UK cases there were also trends towards family history,
earlier age of onset, and the occurrence of more than one primary
melanoma in variant carriers (Table 2).
To extend assessment of the MITF variant in melanoma-prone
families, we screened for E318K in 182 UK families with at least two
melanoma cases and 88 Australian families with at least three cases, all
of which are negative for mutations in CDKN2A or CDK4. Six families
(2.2%)were found to carry the variant. In theUK, E318Kwas enriched
in the more melanoma-dense families; 4/54 (7.4%) families with at
least three melanoma cases versus 1/128 (0.8%) families with two
melanoma cases (Fisher’s exactP5 0.013).We subsequently evaluated
whetherMITF E318K co-segregatedwithmelanoma in these as well as
additional multiple-case families identified from the case–control
sample. In total, we identified 31 unrelated cases carrying MITF
E318K from Australia and the UK with at least one first- or second-
degree relative diagnosed with melanoma (listed in Supplementary
Table 1; Supplementary Fig. 3), 22 of which had DNA available from
additional affected family members for genotyping. In 9/31 families
(five three-case and four two-case families) the variant was found in all
affected individuals (Supplementary Fig. 3a; non-segregating families
shown in Supplementary Fig. 3b), whereas in 12 additional families,
the variant co-segregated with melanoma in the available cases, but
DNA from all cases was not available for screening (Supplementary
Fig. 3c). To test more formally for linkage of melanoma with MITF
E318K in these families, we calculated a lod score of 2.7 under a
dominant model, again consistent with an incompletely penetrant
medium risk variant.
To assess whether theMITF variant is related to knownmelanoma-
associated risk phenotypes of pigmentation and naevus count, we
tested for association both in cases and controls from the Australian
and British populations. TheMITF variant allele is significantly asso-
ciated with increased naevus count (combined P5 0.002, OR 2.54,
95% CI 1.42–4.55; Supplementary Table 2) and non-blue eye colour
(combined P5 0.018, OR 2.01, 95% CI 1.11–3.81; Supplementary
Table 3). It was not associated with skin colour, hair colour, or freck-
ling (Supplementary Table 4). Reassessing the case–control analysis
accounting for naevus count and eye colour gave a slightly reduced
effect size for association of the variant with melanoma (OR 1.82, 95%
CI 0.85–3.92), suggesting that the risk of melanoma attributable to
MITF E318K may be mediated at least in part via one or both of these
phenotypes, but that there is a substantial residual risk conferred by the
variant through an as yet undetermined mechanism.
Wenext sought to evaluatewhether theE318Kmutation altersMITF
function. The E318K variant is located within one of two IKXE con-
sensus sites onMITFpreviously shown to be post-translationallymodi-
fied by the addition of the small ubiquitin-like-modifier SUMO24.
Table 1 | MITF E318K association with melanoma










Australia Cases 34 2,025 0.0165 2.33 1.21–4.70 0.0045 0.0083
Controls 14 1,939 0.0072
UK Cases 34 1,895 0.0176 2.09 1.14–3.94 0.0074 0.0115
Controls 18 2,097 0.0085
Australia 1 UK Cases 68 3,920 0.0171 2.19 1.41–3.45 0.0001 0.0003
Controls 32 4,036 0.0079
It should be noted that the reported allele frequencies forMITF E318K in the population-based samples are without removing individuals with CDKN2A or CDK4mutations, as screening for these genes was not
routinely performed.















All cases 0.0165 34/2,025 2.33 1.21–4.70 0.0176 34/1,895 2.09 1.14–3.94
Age of onset ,40 years 0.0139 14/996 1.95 0.86–4.42 0.0174 5/283 2.10 0.60–5.91
Family history of melanoma 0.0209 12/563 2.95 1.23–6.92 0.0273 3/107 3.36 0.62–11.77
Multiple primary melanomas 0.0296 8/262 4.22 1.52–10.91 0.0225 2/87 2.74 0.30–11.74
Multiple melanomas and family
history
0.0571 6/99 8.37 2.58–23.80 0.0000 0/10 - -
Aus, Australia.
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Mutation of the residue to which SUMO is covalently attached in this
motif (K316R) has previously been shown to abrogateMITF sumoyla-
tion and significantly increase MITF transcriptional activity in
vitro24,25. We thus hypothesized that E318K would similarly alter
sumoylation and transcriptional activity of MITF. To test this we con-
structed a cDNA encoding His-tagged MITF carrying the E318K
mutation. We evaluated the effects of E318K on sumoylation in com-
parison to the wild type and previously characterized synthetic muta-
tions of the twoknownMITF sumoylation sites (K316RandK182R)by
co-transfecting with haemagglutinin (HA)-tagged SUMO1 in COS-7
cells (Fig. 2a). Wild-type MITF shows two SUMO1-modified forms,
whereasMITFmutants K182RorK316R each show only onemodified
form (Fig. 2a). Similar to the synthetic K316R and K182R mutants,
E318K abrogates sumoylation, resulting in complete loss of the doubly
sumoylated form of MITF and reducing the mono-sumoylated form.
When the second site is mutated (K182R) simultaneously with E318K,
MITF sumoylation is completely abolished. Immunoprecipitation
of endogenously expressed MITF E318K from melanoma cells
homozygous for E318K (NAE)when transfectedwith SUMOsimilarly
revealed only bands corresponding to mono- and non-sumoylated
isoforms of MITF on western blot (Fig. 2b).
We then looked for differences between mutant and wild-type
MITF transcriptional activity using a reporter construct containing
the MITF-responsive TRPM1 promoter25. At two concentrations
tested, the E318K mutant exhibited 1.34–1.40 fold induction of the
TRPM1 luciferase reporter relative to wild-type MITF (Fig. 2c). This
fold induction is similar to that observed previously onmultiple MITF
target promoters using single or double artificial sumoylation-site
MITF mutants24,25 and suggests that the E318K variant found in
melanoma changes the transcriptional potency ofMITF. To study this
in greater detail, we determined the effect of the E318K mutation on
global MITF target gene transcription. We developed a tetracycline-
inducible system for expression of wild-type MITF or the E318K vari-
ant in melanoma cell lines with constitutively low or undetectable
levels of endogenous MITF (HT144 and C32, respectively26, Fig. 2d).
At the phenotypic level, induction of wild-type or E318KMITF led to
increased proliferation compared to uninduced controls for each of the
cell lines, although there was no significant difference in growth rate
between the cells expressing the different isoforms (data not shown).
We examined whole-genome expression profiles in these cells follow-
ing induction of either wild-type or E318K MITF for 48 h. Of the 37
genes commonly regulated by wild-type and E318KMITF in both cell
lines (Supplementary Fig. 1a, b; see Methods for analysis details), 28
(76%) had previously been identified as MITF target genes (Sup-
plementary Table 5)27,28, and 17 showed$1.25-fold differences in
expression between the wild-type and E318K isoforms (Supplemen-
tary Fig. 1b). We also identified two gene products that were uniquely
differentially regulated compared to uninduced cells by the induction
of wild-type MITF but not MITF E318K in both parental cell lines,
and 16 gene products after induction of MITF E318K but not wild-
typeMITF (Supplementary Table 6). Of these, 61% (11/18) have previ-
ously been reported as MITF targets (Supplementary Table 6)27,28.
Collectively, these data indicate that the MITF E318Kmutant exhibits
differential transcriptional activity against some, although not all,
target genes. In agreement with the reporter assays (Fig. 2c), we iden-
tified transcriptional differences in gene products known to be
involved in pigmentation (DCT, MLANA), in which the differences
were more marked with expression of the E318K variant in com-
parison to wild-type MITF. These were validated by quantitative
polymerase chain reaction with reverse transcription (qRT–PCR) in
the cell lines used for microarray analysis (Fig. 2e), as well as in an
additional melanoma cell line constitutively expressing wild-type or
E318K mutant MITF (Fig. 2f and Supplementary Fig. 2). In keeping
with the increase in expression of these pigmentation genes, we
detected a 22% increase inmelanin content inHT-144melanoma cells
72 h after induction of MITF E318K compared to wild-type MITF
(data not shown). This is also consistent with our observation that
carriers are more likely to have darker (that is, non-blue) eye colour
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Figure 2 | E318K prevents MITF sumoylation and results in differential
expression of MITF target genes. a, His-tagged wild-type MITF or the
indicated single or double point mutants were co-transfected with HA–
SUMO1 in COS-7 cells or b, HA–SUMO was transfected alone into
homozygous mutant E318KMITFmelanoma cells (NAE). Single- and double-
sumoylated forms of MITF are indicated by a dagger and double dagger,
respectively. The doublet bands are caused by MAPK-mediated
phosphorylation at serine 73 (ref. 30). c, UACC62 humanmelanoma cells were
transfected with TRPM1-promoter constructs with indicated amounts of
expression vector encodingwild-type ormutant forms ofMITF. Fold induction
is shown as the ratio to the average of no MITF transfection (0 ng). Data are
mean6 s.d. of at least four independent experiments. d, Expression ofMITF in
two melanoma cell lines (HT144 and C32) engineered to inducibly express
wild-type (WT) or mutant (E318K) MITF after treatment with tetracycline for
48 h (48), as determined by qRT–PCR. Performed in triplicate, error bars depict
s.d. e, Expression of MITF target genesDCT (top left),MLANA (top right) and
THBS1 (bottom left) determined by qRT–PCR inmelanoma cell lines 48 h after
induction of wild-type or E318K MITF. Gene expression is normalized to
GAPDH and shown as fold change compared to uninduced cells. Performed in
triplicate, error bars denote s.d. f, qRT–PCR analysis of total RNA isolated from
UACC62 human melanoma cells, which were transfected with expression
vector encoding wild-type or mutant forms of MITF. The expression level of
each target gene was normalized toMITF mRNA. Fold induction is shown as
the ratio to each mRNA expression with wild-typeMITF. Data aremean6 s.d.
of at least three independent experiments. *P, 0.05, **P, 0.01.
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previously reported ‘fair-skin-associated’ melanoma risk variants,
such as those inMC1R or TYR. It is uncertain whether the enhanced
expression of pigment genes may contribute to melanomagenesis,
perhaps by increasing oxidative stress and an increase in oxidative
DNA damage29, or alternatively may simply reflect increased MITF
activity, which (separately) promotes tumorigenesis, as MITF is a
previously recognized amplified melanoma oncogene20.
We adopted the approach of whole-genome sequencing of patients
from melanoma families and identified a novel germline mutation of
MITF. This mutation was found to be present in numerous melanoma
families, as well as the general population, in which its association with
melanoma has an effect size similar to red-hair-causing variants of
MC1R23. The melanoma susceptibility genes discovered through
GWAS so far account for only a minority of inherited disease risk. A
proportion of this ‘missing heritability’ may be due to rare sequence
variants, which are poorly detected by GWAS using SNP arrays. The
new MITF variant reported here shows reasonably strong linkage to
melanoma (lod score 2.7) but crucially not a high enough signal to be
clearly visible in previous genome-wide linkage scans.We also provide
in vitro data supporting a functional mechanism by which this muta-
tion may mediate melanoma risk, specifically abrogation of MITF
sumoylation and differential transcription of select MITF target genes.
Although the individual changes in transcription induced by the
mutant E318K MITF in comparison to wild-type MITF are modest,
the orchestrated change in the levels of multiple MITF target genes is
likely to be biologically important, especially over the lifetime of a
person. This study offers a rare glimpse of a complex functionality
whereby a risk-conferring SNP affects the post-translational proces-
sing of a crucial lineage-specific survival and differentiation gene. This
study demonstrates the utility of performing whole-genome and
exome resequencing in appropriate affected individuals to identify
such novel rare disease-specific variants and functionally characterize
variants associated with complex disease not otherwise detectable via
GWAS or linkage approaches.
METHODS SUMMARY
The collection of the Australian melanoma families used for the study, as well as
the Queensland and AMFS case–control sets are described elsewhere and in
Methods. Likewise the UK studies from Leeds and Cambridge as well as the panel
of melanoma cell lines. Whole-genome sequencing, assembly and variant calling
were performed by Complete Genomics, as described previously14. Genotyping of
MITF E318K was performed using the SequenomMassArray system (Australian
studies) or a custom TaqMan assay (UK studies), with DNA from the affected
family member in which E318K was identified included multiple times as a
positive control. Statistical analyses are described in detail in Methods. Co-
segregation analyses were performed inmelanoma families via Sanger sequencing
using the primers: forward, 59-CAGGCTCGAGCTCATGGA-39; reverse,
59-TGGGGACACTATAGGCTTGG-39. MITF sumoylation andTRPM1 reporter
assays were performed as previously described25.
Full Methods and any associated references are available in the online version of
the paper at www.nature.com/nature.
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METHODS
Melanoma families.Ascertainment and clinical evaluation of Australian and UK
pedigrees with familial melanoma is described elsewhere31–35. In an effort to
maximize the chance of identifying a novel melanoma susceptibility gene, we
restricted inclusion in our study to pedigrees that were mutation negative for both
CDKN2A and CDK4, by single-strand conformation polymorphism (SSCP)
and/or direct sequencing.
Melanoma case–control studies. Australia. Cases were drawn from (1) a
population-based sample from Queensland, unselected for age at onset
(Queensland study of Melanoma: Environment and Genetic Associations;
Q-MEGA36) and (2) a population-based case–control family study of melanoma
diagnosed before age 40 years, ascertained in Brisbane, Melbourne and Sydney
(AMFS)37. Two sets of Australian controls were used. First, a sample of unrelated
individuals was ascertained; they were mainly parents of adolescent twins (80% of
the sample), together with a smaller number of twins and their siblings, recruited
through schools to participate in the Brisbane Adolescent Twin Study38.
Additionally, a set of controls from AMFS were available for genotyping37. The
AMFS and twin controls did not have a personal history of melanoma. Approval
for these as well as the melanoma family studies was obtained from the Human
Research Ethics Committees of Queensland Institute of Medical Research
(QIMR), University of Sydney, University of Melbourne and cancer registries of
New SouthWales, Victoria andQueensland. Informed consent was obtained from
all participants. Most samples had: questionnaire-based naevus count based on a
four point scale: ‘none’, ‘a few’, ‘moderate’ and ‘very many’ (Queensland); or
‘none’, ‘few’, ‘some’ and ‘many’ for AMFS; data on pigmentation variables, includ-
ing: hair colour (fair, light brown, red, dark brown, black), eye colour (blue/grey,
green hazel, brown/black), skin colour (light, medium, dark) and number of
freckles (none, few, some/moderate, many).
United Kingdom. The Leeds-based case-control study recruited population-
based incident melanoma cases diagnosed between September 2000 and
December 2006 from a geographically defined area of Yorkshire and the
Northern region of the UK (63% response rate)9,12,39. Cases were identified by
clinicians and pathology registers and via the Northern and Yorkshire Cancer
Registry and Information Service to ensure overall ascertainment. For all but 18
months of the study period, recruitment was restricted to patients with Breslow
thickness of at least 0.75mm. Controls were ascertained by contacting general
practitioners to identify eligible individuals. These controls were frequency-
matched with cases for age and sex from general practitioners who had also had
cases as a part of their patient register. Overall there was a 55% response rate for
controls. The first 960 of the cases recruited and all controls were examined by
trained interviewers who performed a standardized examination of the skin,
recording naevi by anatomical site and size. For subsequent cases, self-reported
information on naevi was obtained. In total we utilized 1,549 cases and 495 con-
trols from this study. We also used 380 cases and 373 controls recruited by the
University of Cambridge who were genotyped in the replication series. The cases
and controls were recruited as a part of the SEARCH study40,41, an ongoing
population-based study in Eastern England. Cases were ascertained through the
Eastern Cancer Registry and Information Centre, and were aged between 18 and
70 years at diagnosis. Controlswere drawn fromSEARCHandEPIC-Norfolk. The
control set was supplemented with 1,245 additional controls from the Wellcome
Trust Blood Services control set. Details of these studies have been previously
published40–42. Approvals for the Leeds-based family studies, the Leeds case–
control study and the Leeds Melanoma Cohort study were obtained from the
National Research Ethics Service, Northern and Yorkshire Research Ethics
Committee. Approvals for Cambridge case–control studies were obtained from
the Cambridgeshire 4 Research Ethics Committee and the Norwich Local
Research Ethics Committee. Informed consent was obtained from all participants.
Melanoma cell lines. The melanoma tumour cell lines used in this study were
derived from primary cutaneous melanomas or melanoma metastases, as
described previously43. DNA was extracted using QIAGEN QIamp Blood Maxi
kits (Qiagen) according to the manufacturer’s instructions.
DNA Sequencing (whole genome). One affected member from Family 1 was
sequencedbyCompleteGenomics usingananoarray-based short-read sequencing-
by-ligation strategy. Sequencing, genome assembly (to genome build hg18/
NCBI36.1), and variant calling were performed as described previously14.
SequenomMassARRAY genotyping of E318K.MITF E318K was genotyped in
Australian samples as part of a multiplex assay designed using the Sequenom
MassARRAY Assay Design software (version 3.0). The SNP was typed using
Sequenom iPLEX chemistry on a MALDI-TOF Compact Mass Spectrometer
(Sequenom). The 2.5ml PCR reactions were performed in standard 384-well plates
using 12.5 ng genomic DNA, 0.8 units of Taq polymerase (HotStarTaq, Qiagen),
500mmol of each dNTP, 1.625mM of MgCl2 and 100nmol of each PCR primer
(Bioneer). Standard PCR thermal cycling conditions and post-PCR extension
reactions were carried out as described previously10. The iPLEX reaction products
were desalted by diluting samples with 15ml of water and adding 3ml of resin. The
productswere spotted on a SpectroChip (Sequenom), anddatawere processed and
analysed byMassARRAYTYPER3.4 software (Sequenom).DNA from the Family
1 sample in which E318K was identified was included multiple times as a positive
control. As an additional quality control measure, we also confirmed the genotype
of multiple individuals from the Australian case–control study, particularly those
with a family history of melanoma, via Sanger sequencing, identifying no geno-
typing errors.
TaqMan genotyping of E318K. UK samples were genotyped for E318K using a
customTaqMan assay. DNA from the Australian familymember in which E318K
was identified was included as a positive control. Leeds melanoma pedigrees also
were re-screened as a quality control measure using high-resolution melting
(HRM) primers designed to assay E318K, with the results from HRM and
TaqMan matching exactly.
Statistical analyses. Parametric linkage analysis on the multiple case melanoma
families was conducted assuming a dominant model of inheritance, with
penetrances specified as 5%, 95%, 95% for the three genotype classes. The allele
frequency at the disease andmarker locus was specified to be 0.004. Computations
were done using the standard (lod score) parametric linkage routine implemented
in GENEHUNTER-MODSCORE44. For melanoma case–control status, number
of cases carrying the variant was compared to number of controls carrying the
variant using Fisher’s exact test. P values given are two-sided except where noted
otherwise. Sub-phenotypes were tested similarly, with family history, age at onset
and multiple primary melanoma carrier rates compared with that in controls.
Number of blue-eyed individuals carrying the variant was compared to number
of non-blue eyed individuals carrying the variant using Fisher’s exact test. Meta-
analysis for disease/sub-phenotype status and eye colour was done by combining
the raw data. Association with mole count (high versus low where high was
Australian Q-MEGA ‘moderate/many’, Australian AMFS ‘some/many’, UK
‘.25 moles’ and low was Australian Q-MEGA ‘none/few’, Australian AMFS
‘none/few’, UK ‘,25 moles’) was tested using Fisher’s exact test for each sample
individually, due to differences in the exact definition of low/high. Meta-analysis
results for mole count were generated by combining the individual sample ORs
(where the natural log of the odds ratio was weighted for each sample by the
inverse variance of the natural log of the odds ratio). The case–control analysis
corrected for naevus count and eye colour was computed by fitting a logistic
regression with naevus count and eye colour categories as covariates.
Sanger sequencing for E318K. Australian pedigrees for which the proband was
identified as carrying the E318K variant via Sequenom, as well as the panel of
melanoma cell lines, were screened for E318K via Sanger sequencing using the
following primers: forward, 59-CAGGCTCGAGCTCATGGA-39; reverse,
59- TGGGGACACTATAGGCTTGG-39.
MITF sumoylation assay. His–MITF and/or HA–SUMO1 expression vectors,
previously described25, were transfected into COS-7 or NAE cells. The cells were
harvested after three days and 10mg total protein was applied to each lane.
Western blots were performed with anti-MITF monoclonal antibody (C5).
TRPM1 reporter assay. TRPM1 reporter plasmid (100 ng), Renilla luciferase
vector (1 ng) (as internal control), and MITF expression vector (0, 175 or
350ng) were transfected into UACC62 human melanoma cells as previously
described25. After 2 days, luciferase activity was determined. Transfection effi-
ciency was normalized to Renilla luciferase activity. Results are reported as the
average of at least four independent experiments.
Construction of inducibleMITF-expressing cell lines. Stable inducible express-
ion of MITF was achieved using the ViraPower T-REx Lentiviral Expression
System (Invitrogen). Briefly, cell pools were transduced with lentiviral particles
containing pLENTI6/TR, and selected with 3mgml21 blasticidin. Wild-type
MITF was cloned into pLENTI4/TO/V5-DEST using Gateway recombination.
Site-directed mutagenesis of the putative sumolyation site was carried out using
a QuickChange II XL site-directed mutagenesis kit (Stratagene/Agilent
Technologies), and the following primer pair: E318K change: E318K forward,
59- GGTGAATCGGATCATCAAGCAAAAACCCGTTCTTG -39 and E318K
reverse, 59- CAAGAACGGGTTTTTGCTTGATGATCCGATTCACC -39. The
negative control construct was identical except that it encodes the b-galactosidase
gene (Invitrogen). Lentivirus particles were packaged in 293FT cells, before being
titred usingMM96L cells. Target melanoma cell lines were transduced withMITF
and mutant particles using a multiplicity of infection of less than 1, and selected
with 500mgml21 zeocin and 1mgml21 blasticidin for 3 weeks. Cells were main-
tained on 100mgml21 zeocin and 0.5mgml21 blasticidin for all experiments.
Induction of MITF. Cells were treated the day after seeding with 1mgml21
tetracycline to induce MITF expression, and harvested 24 or 48 h afterwards.
RNA was extracted using Qiagen RNeasy mini kit as per manufacturer’s instruc-
tions. RNA concentration was determined using the NanoDrop 2000 (Thermo
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Scientific). For mRNA analyses 0.5mg of total RNA was reverse transcribed using
Superscript III according to the manufacturer’s instructions (Invitrogen) and
MITF, DCT, MLANA, TBSP1 and GAPDH expression analysed using SYBR
Green PCR Master Mix (Applied Biosystems). Primer sequences were MITF
forward, 59-CCAAGTACCACATACAGCAAGC-39 and MITF reverse, 59-TCA
TCCATCTGCATACAGGACG-39, DCT forward 59-CGACTCTGATTAGTCG
GAACTCA-39 and DCT reverse, 59-GGTGGTTGTAGTCATCCAAGC-39,
MLANA forward, 59- GAGAAAAACTGTGAACCTGTGGT-39 and MLANA
reverse, 59- GACTGTTCTGCAGAGAGTTTCTCAT-39, THBS1 forward,
59-CGGTCCAGACACGGACCTGC-39 and THBS1 reverse 59-GGCTTTGG
TCTCCCGCGCTT-39, GAPDH forward, 59-GGCTCTCCAGAACATCATCC
CTGC-39 and GAPDH reverse, 59-GGGTGTCGCTGTTGAAGTCAGAGG -39.
qRT–PCR was performed using a 7900HT Fast Real Time PCR System (Applied
Biosystems).
Generation of constitutive MITF-expressing melanoma cell lines. pcDNA4.1-
HisMax-hMITF (wild type, E318K or K182R/K316R) and pEGFP-C1 (for selec-
tion with G418) were transfected into the UACC62 melanoma cell line. After 5
days of selection with G418, total RNA was collected and MITF target gene
transcript levels assessed by quantitative RT–PCR using the Pfaffl method45.
Expression profiling and analysis. Biotinylated cRNA was prepared with the
Illumina TotalPrep RNA Amplification Kit (Ambion). Labelled cRNA was
hybridized to HumanHT-12 v4 BeadChip Arrays (Illumina), and then washed
and scanned according to standard Illumina protocols. Data were extracted in
GenomeStudio (Illumina) using default analysis settings and no normalization
method. Resulting data were imported into GeneSpring GX v11.5 (Agilent
Technologies). Expression values were normalized using quantile normalization
with default settings.
Entities at least 1.5 fold up- or downregulated following induction of either
wild-type or E318KMITF were determined (C32 wild type, 491; C32 E318K, 705;
HT144wild type, 273;HT144 E318K, 450). Targets similarly up-or downregulated
only by E318K and not wild-type MITF in both of the melanoma cell lines were
identified using Venn diagram (n5 16 entities). Also targets similarly up- or
downregulated only by wild-type and not E318K MITF in both of the melanoma
cell lines were identified usingVenndiagram (n5 2 entities). Entities similarly up-
or downregulated by induction of wild-type and E318K MITF were identified
(C32 wild type and E318K, 244; HT144 wild type and E318K, 150), and those
targets consistently differentially expressed in both of the cell lines identified by
Venn diagram (n5 43 entities representing 37 gene products).
NCBI GEO (http://www.ncbi.nlm.nih.gov/geo/) accession numbers are as fol-
lows: GEO Series reference, GSE31269; GSM774914 HT144wild-type uninduced;
GSM774915 HT144 wild-type 48 h induced; GSM774916 HT144 E318K
uninduced; GSM774917 HT144 E318K 48 h induced; GSM774918 C32 wild-type
uninduced; GSM774919 C32 wild-type 48 h induced; GSM774920 C32 E318K
uninduced; GSM774921 C32 E318K 48 h induced.
Melanin quantification assay.Melanin levels were determined46 after 72 h induc-
tion of wild-type or E318K MITF, and normalized to amounts in uninduced
control cells. Values are from duplicate readings from triplicate independent
experiments.
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